Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

324 ARTÍCULOS , VIENDO DEL 241 AL 255

Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment

Visser PJ, Wolf H, Frisoni G, Gertz HJ.

Biomark Med. 2012 Aug;6(4):365-8. doi: 10.2217/bmm.12.58.

Analytical aspects of molecular Alzheimer's disease biomarkers

Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H.

Biomark Med. 2012 Aug;6(4):377-89. doi: 10.2217/bmm.12.44.

Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges

Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, Schott JM.

Biomark Med. 2012 Aug;6(4):391-400. doi: 10.2217/bmm.12.49.

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers

Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, Zetterberg H, Blennow K.

Biomark Med. 2012 Aug;6(4):401-7. doi: 10.2217/bmm.12.41.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42

Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E.

Biomark Med. 2012 Aug;6(4):409-17. doi: 10.2217/bmm.12.39.

Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease

Herholz K.

Biomark Med. 2012 Aug;6(4):431-9. doi: 10.2217/bmm.12.51.

Plasma biomarkers for Alzheimer's disease: much needed but tough to find

Bazenet C, Lovestone S.

Biomark Med. 2012 Aug;6(4):441-54. doi: 10.2217/bmm.12.48.

Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease

Fagan AM, Perrin RJ.

Biomark Med. 2012 Aug;6(4):455-76. doi: 10.2217/bmm.12.42.

Mild cognitive impairment: a subset of minor neurocognitive disorder?

Geda YE, Nedelska Z.

Am J Geriatr Psychiatry. 2012 Oct;20(10):821-6. doi: 10.1097/JGP.0b013e31826abc00.

Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer's disease

Höglund K, Bogstedt A, Fabre S, Aziz A, Annas P, Basun H, Minthon L, Lannfelt L, Blennow K, Andreasen N.

J Alzheimers Dis. 2012;32(4):939-47. doi: 10.3233/JAD-2012-120976.

[Markers of prodromal Alzheimer's disease]

de Souza LC, Sarazin M, Uspenskaya O, Habert MO, Lamari F, Lehéricy S, Dubois B.

Rev Neurol (Paris). 2012 Nov;168(11):815-24. doi: 10.1016/j.neurol.2012.07.005. Epub 2012 Sep 1.

Fluid biomarkers in Alzheimer disease

Blennow K, Zetterberg H, Fagan AM.

Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006221. doi: 10.1101/cshperspect.a006221.

Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias

Genius J, Klafki H, Benninghoff J, Esselmann H, Wiltfang J.

Eur Arch Psychiatry Clin Neurosci. 2012 Nov;262 Suppl 2:S71-7. doi: 10.1007/s00406-012-0362-3. Epub 2012 Sep 18.

Marking the markers of Alzheimer's: too good to diagnose, too bad to use?

Olah Z, Pakaski M, Janka Z, Kalman J.

Neuropsychopharmacol Hung. 2012 Sep;14(3):165-76.

Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease

Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X, Cook JJ, Simon AJ, Savage MJ.

J Neurosci Res. 2012 Dec;90(12):2247-58. doi: 10.1002/jnr.23122. Epub 2012 Sep 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias